A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors.

Part of paid clinical trials in Nashville, Tennessee.

Sponsor
Erasca, Inc.
Study ID
NCT07021898
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Metastatic Solid Tumors

Eligibility Criteria

Sex
ALL
Age
18 Years - 99 Years
Healthy Volunteers
Not accepted

Interventions

  • ERAS-4001 — DRUG
    ERAS-4001 Administered orally
  • ERAS-4001 in combination — DRUG
    ERAS-4001 Administered orally and in combination with either Keytruda (pembrolizumab) via IV administration or Vectibix (panitumumab) via IV administration.

Study Details

The main purpose of the study is to assess whether the study drug, ERAS-4001, is safe and tolerable when administered to patients with advanced or metastatic solid tumors with certain KRAS mutations. ERAS-4001 will be given alone or in combination with other treatments.

Key Dates

Start date
Aug 6, 2025
Status verified
Dec 2025
Primary completion
Aug 31, 2028
Completion
Dec 31, 2028

Study Design

Enrollment
200 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: ERAS-4001 Monotherapy Dose Optimization.
    Escalating doses of ERAS-4001 administered orally.
  • Experimental: ERAS-4001 Combination Dose Optimization
    ERAS-4001 administered orally with another investigational agent.

Primary Outcome Measure

Dose Limiting Toxicities (DLT) [ Time Frame: Study Day 1 up to Day 21 ]

Central Contacts

Locations (5)

FacilityCityStateZIPSite coordinators
Sarah Cannon Research Institute (SCRI) Oncology PartnersNashvilleTennessee32703-
The University of Texas MD Anderson Cancer CenterHoustonTexas77030-
NEXT OncologyIrvingTexas75039-
NEXT OncologySan AntonioTexas78229-
Fred Hutchinson Cancer CenterSeattleWashington98109-

Find similar trials in Nashville, TN

By research site
Sarah Cannon Research Institute (SCRI) Oncology Partners· Nashville, TNThe University of Texas MD Anderson Cancer Center· Houston, TXNEXT Oncology· Irving, TXNEXT Oncology· San Antonio, TXFred Hutchinson Cancer Center· Seattle, WA

Related Studies